Health Condition 1: J32- Chronic sinusitis Health Condition 2: F01-F99- Mental, Behavioral and Neurodevelopmental disorders
Conditions
Interventions
Intervention1: Polyherbal Unani Formulation: Dosage Form: Decoction Using Raw Drugs
Dose: 45gm Daily One Time
Duration: 42 days
Route of Administration: Oral
Composition of Formulation:
1- Aslussoos (
Sponsors
National Research Institute of Unani Medicine for Skin Disorders, Hyederabad
Eligibility
Inclusion criteria
Inclusion criteria: 1. Duration of the disease >12 week. 2. Patient having at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal obstruction, and nasal discharge for at least 12 consecutive weeks. 3. Patient having other symptoms rhinorrhea, nasal congestion, frontal headache, nasal itching, impaired sense of smell and frequent sneezing for more than 12 weeks. 4. Positive X-ray PNS finding (Thickened mucosal lining, opacity of sinus).
Exclusion criteria
Exclusion criteria: 1. Patient aged 50 years. 2. Patient with deviated nasal septum(DNS). 3. Local pathology such as mucocele, cyst, antrochoanal polyp, facial trauma. 4. Diabetes mellitus and any other illness requiring long term treatment. 5. Pregnant or Lactating Women. 6. Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction 7. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/Malignancies. 8. Patient not willing to attend regular treatment and follow-up for the entire duration of study. 9. Mentally retarded patients. 10.Patient having history of any surgery of nose or paranasal sinuses. 11. Patient having history of trauma to nose or sinus area. 12. Patient of pulmonary Kochâ??s or having history of epistaxis. 13. Any medical condition where physician feels that participation in the study could be detrimental to patientâ??s well being. 14. Alcoholic and Drug addicted patient. 15. Patient having allergy of controlled drug or with any of the ingredients of test drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the Grading of X-ray PNS (Thickened mucosal lining, opacity of sinus) Reduction in SNOT-22 Score Reduction in VAS Score Reduction in Serum Level of Ig E Timepoint: 42 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Systemic Safety AssessmentTimepoint: 42 days | — |
Countries
India
Contacts
Public ContactFazila Nawab
National Research Institute of Unani Medicine for skin disorders
Outcome results
None listed